The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Kidney Cancer Drugs Market Research Report 2025

Global Kidney Cancer Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1805437

No of Pages : 111

Ask Your Query

Synopsis

Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.

The global Kidney Cancer Drugs market was valued at US$ 3970.1 million in 2023 and is anticipated to reach US$ 5501.9 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.

Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.

This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Drugs.

Report Scope

The Kidney Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Kidney Cancer Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company  (Partial List)

  • Bayer
  • Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Abbott Laboratories
  • Active Biotech
  • Amgen
  • Argos Therapeutics
  • ArQule
  • AVEO Pharmaceuticals
  • Bionomics
  • Bristol-Myers Squibb
  • Cerulean Pharma
  • Exelixis
  • Genentech
  • immatics biotechnologies
  • Immunicum
  • Ono Pharmaceutical
  • Onyx Therapeutics
  • Oxford BioMedica
  • Prometheus Laboratories
  • Seattle Genetics
  • Taiwan Liposome
  • Tracon Pharmaceuticals
  • Wilex

Segment by Type

  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Monoclonal Antibodies
  • Cytokine Immunotherapy (IL-2)

Segment by Application

  • Renal Cell Carcinoma (RCC)
  • Transitional Cell Carcinoma (TCC)

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Kidney Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Kidney Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Kidney Cancer Drugs Market Overview
1.1 Product Overview and Scope of Kidney Cancer Drugs
1.2 Kidney Cancer Drugs Segment by Type
1.2.1 Global Kidney Cancer Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Angiogenesis Inhibitors
1.2.3 mTOR Inhibitors
1.2.4 Monoclonal Antibodies
1.2.5 Cytokine Immunotherapy (IL-2)
1.3 Kidney Cancer Drugs Segment by Application
1.3.1 Global Kidney Cancer Drugs Market Value by Application: (2024-2030)
1.3.2 Renal Cell Carcinoma (RCC)
1.3.3 Transitional Cell Carcinoma (TCC)
1.4 Global Kidney Cancer Drugs Market Size Estimates and Forecasts
1.4.1 Global Kidney Cancer Drugs Revenue 2019-2030
1.4.2 Global Kidney Cancer Drugs Sales 2019-2030
1.4.3 Global Kidney Cancer Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Kidney Cancer Drugs Market Competition by Manufacturers
2.1 Global Kidney Cancer Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Kidney Cancer Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Kidney Cancer Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Kidney Cancer Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Kidney Cancer Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Kidney Cancer Drugs, Product Type & Application
2.7 Kidney Cancer Drugs Market Competitive Situation and Trends
2.7.1 Kidney Cancer Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Kidney Cancer Drugs Players Market Share by Revenue
2.7.3 Global Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Kidney Cancer Drugs Retrospective Market Scenario by Region
3.1 Global Kidney Cancer Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Kidney Cancer Drugs Global Kidney Cancer Drugs Sales by Region: 2019-2030
3.2.1 Global Kidney Cancer Drugs Sales by Region: 2019-2024
3.2.2 Global Kidney Cancer Drugs Sales by Region: 2025-2030
3.3 Global Kidney Cancer Drugs Global Kidney Cancer Drugs Revenue by Region: 2019-2030
3.3.1 Global Kidney Cancer Drugs Revenue by Region: 2019-2024
3.3.2 Global Kidney Cancer Drugs Revenue by Region: 2025-2030
3.4 North America Kidney Cancer Drugs Market Facts & Figures by Country
3.4.1 North America Kidney Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Kidney Cancer Drugs Sales by Country (2019-2030)
3.4.3 North America Kidney Cancer Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Kidney Cancer Drugs Market Facts & Figures by Country
3.5.1 Europe Kidney Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Kidney Cancer Drugs Sales by Country (2019-2030)
3.5.3 Europe Kidney Cancer Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Kidney Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Kidney Cancer Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Kidney Cancer Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Kidney Cancer Drugs Market Facts & Figures by Country
3.7.1 Latin America Kidney Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Kidney Cancer Drugs Sales by Country (2019-2030)
3.7.3 Latin America Kidney Cancer Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Kidney Cancer Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Kidney Cancer Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Kidney Cancer Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Kidney Cancer Drugs Sales by Type (2019-2030)
4.1.1 Global Kidney Cancer Drugs Sales by Type (2019-2024)
4.1.2 Global Kidney Cancer Drugs Sales by Type (2025-2030)
4.1.3 Global Kidney Cancer Drugs Sales Market Share by Type (2019-2030)
4.2 Global Kidney Cancer Drugs Revenue by Type (2019-2030)
4.2.1 Global Kidney Cancer Drugs Revenue by Type (2019-2024)
4.2.2 Global Kidney Cancer Drugs Revenue by Type (2025-2030)
4.2.3 Global Kidney Cancer Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Kidney Cancer Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Kidney Cancer Drugs Sales by Application (2019-2030)
5.1.1 Global Kidney Cancer Drugs Sales by Application (2019-2024)
5.1.2 Global Kidney Cancer Drugs Sales by Application (2025-2030)
5.1.3 Global Kidney Cancer Drugs Sales Market Share by Application (2019-2030)
5.2 Global Kidney Cancer Drugs Revenue by Application (2019-2030)
5.2.1 Global Kidney Cancer Drugs Revenue by Application (2019-2024)
5.2.2 Global Kidney Cancer Drugs Revenue by Application (2025-2030)
5.2.3 Global Kidney Cancer Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Kidney Cancer Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Kidney Cancer Drugs Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Roche Kidney Cancer Drugs Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline Kidney Cancer Drugs Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Kidney Cancer Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Kidney Cancer Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott Laboratories
6.6.1 Abbott Laboratories Corporation Information
6.6.2 Abbott Laboratories Description and Business Overview
6.6.3 Abbott Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Abbott Laboratories Kidney Cancer Drugs Product Portfolio
6.6.5 Abbott Laboratories Recent Developments/Updates
6.7 Active Biotech
6.6.1 Active Biotech Corporation Information
6.6.2 Active Biotech Description and Business Overview
6.6.3 Active Biotech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Active Biotech Kidney Cancer Drugs Product Portfolio
6.7.5 Active Biotech Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Amgen Kidney Cancer Drugs Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 Argos Therapeutics
6.9.1 Argos Therapeutics Corporation Information
6.9.2 Argos Therapeutics Description and Business Overview
6.9.3 Argos Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Argos Therapeutics Kidney Cancer Drugs Product Portfolio
6.9.5 Argos Therapeutics Recent Developments/Updates
6.10 ArQule
6.10.1 ArQule Corporation Information
6.10.2 ArQule Description and Business Overview
6.10.3 ArQule Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 ArQule Kidney Cancer Drugs Product Portfolio
6.10.5 ArQule Recent Developments/Updates
6.11 AVEO Pharmaceuticals
6.11.1 AVEO Pharmaceuticals Corporation Information
6.11.2 AVEO Pharmaceuticals Kidney Cancer Drugs Description and Business Overview
6.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 AVEO Pharmaceuticals Kidney Cancer Drugs Product Portfolio
6.11.5 AVEO Pharmaceuticals Recent Developments/Updates
6.12 Bionomics
6.12.1 Bionomics Corporation Information
6.12.2 Bionomics Kidney Cancer Drugs Description and Business Overview
6.12.3 Bionomics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Bionomics Kidney Cancer Drugs Product Portfolio
6.12.5 Bionomics Recent Developments/Updates
6.13 Bristol-Myers Squibb
6.13.1 Bristol-Myers Squibb Corporation Information
6.13.2 Bristol-Myers Squibb Kidney Cancer Drugs Description and Business Overview
6.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Bristol-Myers Squibb Kidney Cancer Drugs Product Portfolio
6.13.5 Bristol-Myers Squibb Recent Developments/Updates
6.14 Cerulean Pharma
6.14.1 Cerulean Pharma Corporation Information
6.14.2 Cerulean Pharma Kidney Cancer Drugs Description and Business Overview
6.14.3 Cerulean Pharma Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Cerulean Pharma Kidney Cancer Drugs Product Portfolio
6.14.5 Cerulean Pharma Recent Developments/Updates
6.15 Exelixis
6.15.1 Exelixis Corporation Information
6.15.2 Exelixis Kidney Cancer Drugs Description and Business Overview
6.15.3 Exelixis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Exelixis Kidney Cancer Drugs Product Portfolio
6.15.5 Exelixis Recent Developments/Updates
6.16 Genentech
6.16.1 Genentech Corporation Information
6.16.2 Genentech Kidney Cancer Drugs Description and Business Overview
6.16.3 Genentech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Genentech Kidney Cancer Drugs Product Portfolio
6.16.5 Genentech Recent Developments/Updates
6.17 immatics biotechnologies
6.17.1 immatics biotechnologies Corporation Information
6.17.2 immatics biotechnologies Kidney Cancer Drugs Description and Business Overview
6.17.3 immatics biotechnologies Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.17.4 immatics biotechnologies Kidney Cancer Drugs Product Portfolio
6.17.5 immatics biotechnologies Recent Developments/Updates
6.18 Immunicum
6.18.1 Immunicum Corporation Information
6.18.2 Immunicum Kidney Cancer Drugs Description and Business Overview
6.18.3 Immunicum Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Immunicum Kidney Cancer Drugs Product Portfolio
6.18.5 Immunicum Recent Developments/Updates
6.19 Ono Pharmaceutical
6.19.1 Ono Pharmaceutical Corporation Information
6.19.2 Ono Pharmaceutical Kidney Cancer Drugs Description and Business Overview
6.19.3 Ono Pharmaceutical Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Ono Pharmaceutical Kidney Cancer Drugs Product Portfolio
6.19.5 Ono Pharmaceutical Recent Developments/Updates
6.20 Onyx Therapeutics
6.20.1 Onyx Therapeutics Corporation Information
6.20.2 Onyx Therapeutics Kidney Cancer Drugs Description and Business Overview
6.20.3 Onyx Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Onyx Therapeutics Kidney Cancer Drugs Product Portfolio
6.20.5 Onyx Therapeutics Recent Developments/Updates
6.21 Oxford BioMedica
6.21.1 Oxford BioMedica Corporation Information
6.21.2 Oxford BioMedica Kidney Cancer Drugs Description and Business Overview
6.21.3 Oxford BioMedica Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Oxford BioMedica Kidney Cancer Drugs Product Portfolio
6.21.5 Oxford BioMedica Recent Developments/Updates
6.22 Prometheus Laboratories
6.22.1 Prometheus Laboratories Corporation Information
6.22.2 Prometheus Laboratories Kidney Cancer Drugs Description and Business Overview
6.22.3 Prometheus Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Prometheus Laboratories Kidney Cancer Drugs Product Portfolio
6.22.5 Prometheus Laboratories Recent Developments/Updates
6.23 Seattle Genetics
6.23.1 Seattle Genetics Corporation Information
6.23.2 Seattle Genetics Kidney Cancer Drugs Description and Business Overview
6.23.3 Seattle Genetics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Seattle Genetics Kidney Cancer Drugs Product Portfolio
6.23.5 Seattle Genetics Recent Developments/Updates
6.24 Taiwan Liposome
6.24.1 Taiwan Liposome Corporation Information
6.24.2 Taiwan Liposome Kidney Cancer Drugs Description and Business Overview
6.24.3 Taiwan Liposome Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Taiwan Liposome Kidney Cancer Drugs Product Portfolio
6.24.5 Taiwan Liposome Recent Developments/Updates
6.25 Tracon Pharmaceuticals
6.25.1 Tracon Pharmaceuticals Corporation Information
6.25.2 Tracon Pharmaceuticals Kidney Cancer Drugs Description and Business Overview
6.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.25.4 Tracon Pharmaceuticals Kidney Cancer Drugs Product Portfolio
6.25.5 Tracon Pharmaceuticals Recent Developments/Updates
6.26 Wilex
6.26.1 Wilex Corporation Information
6.26.2 Wilex Kidney Cancer Drugs Description and Business Overview
6.26.3 Wilex Kidney Cancer Drugs Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Wilex Kidney Cancer Drugs Product Portfolio
6.26.5 Wilex Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Kidney Cancer Drugs Industry Chain Analysis
7.2 Kidney Cancer Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Kidney Cancer Drugs Production Mode & Process
7.4 Kidney Cancer Drugs Sales and Marketing
7.4.1 Kidney Cancer Drugs Sales Channels
7.4.2 Kidney Cancer Drugs Distributors
7.5 Kidney Cancer Drugs Customers
8 Kidney Cancer Drugs Market Dynamics
8.1 Kidney Cancer Drugs Industry Trends
8.2 Kidney Cancer Drugs Market Drivers
8.3 Kidney Cancer Drugs Market Challenges
8.4 Kidney Cancer Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Kidney Cancer Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Kidney Cancer Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Kidney Cancer Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Kidney Cancer Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Kidney Cancer Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Kidney Cancer Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Kidney Cancer Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Kidney Cancer Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Kidney Cancer Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Kidney Cancer Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Kidney Cancer Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Kidney Cancer Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Kidney Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Kidney Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Kidney Cancer Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Kidney Cancer Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Kidney Cancer Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Kidney Cancer Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Kidney Cancer Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Kidney Cancer Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Kidney Cancer Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Kidney Cancer Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Kidney Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Kidney Cancer Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Kidney Cancer Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Kidney Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Kidney Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Kidney Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Kidney Cancer Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Kidney Cancer Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Kidney Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Kidney Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Kidney Cancer Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Kidney Cancer Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Kidney Cancer Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Kidney Cancer Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Kidney Cancer Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Kidney Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Kidney Cancer Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Kidney Cancer Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Kidney Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Kidney Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Kidney Cancer Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Kidney Cancer Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Kidney Cancer Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Kidney Cancer Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Kidney Cancer Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Kidney Cancer Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Kidney Cancer Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Kidney Cancer Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Kidney Cancer Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Kidney Cancer Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Kidney Cancer Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Kidney Cancer Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Kidney Cancer Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Kidney Cancer Drugs Price (USD/Unit) by Type (2019-2024)
Table 59. Global Kidney Cancer Drugs Price (USD/Unit) by Type (2025-2030)
Table 60. Global Kidney Cancer Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Kidney Cancer Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Kidney Cancer Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Kidney Cancer Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Kidney Cancer Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Kidney Cancer Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Kidney Cancer Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Kidney Cancer Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Kidney Cancer Drugs Price (USD/Unit) by Application (2019-2024)
Table 69. Global Kidney Cancer Drugs Price (USD/Unit) by Application (2025-2030)
Table 70. Bayer Corporation Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Bayer Kidney Cancer Drugs Product
Table 74. Bayer Recent Developments/Updates
Table 75. Roche Corporation Information
Table 76. Roche Description and Business Overview
Table 77. Roche Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Roche Kidney Cancer Drugs Product
Table 79. Roche Recent Developments/Updates
Table 80. GlaxoSmithKline Corporation Information
Table 81. GlaxoSmithKline Description and Business Overview
Table 82. GlaxoSmithKline Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. GlaxoSmithKline Kidney Cancer Drugs Product
Table 84. GlaxoSmithKline Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Novartis Kidney Cancer Drugs Product
Table 89. Novartis Recent Developments/Updates
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Pfizer Kidney Cancer Drugs Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Abbott Laboratories Corporation Information
Table 96. Abbott Laboratories Description and Business Overview
Table 97. Abbott Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Abbott Laboratories Kidney Cancer Drugs Product
Table 99. Abbott Laboratories Recent Developments/Updates
Table 100. Active Biotech Corporation Information
Table 101. Active Biotech Description and Business Overview
Table 102. Active Biotech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Active Biotech Kidney Cancer Drugs Product
Table 104. Active Biotech Recent Developments/Updates
Table 105. Amgen Corporation Information
Table 106. Amgen Description and Business Overview
Table 107. Amgen Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Amgen Kidney Cancer Drugs Product
Table 109. Amgen Recent Developments/Updates
Table 110. Argos Therapeutics Corporation Information
Table 111. Argos Therapeutics Description and Business Overview
Table 112. Argos Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Argos Therapeutics Kidney Cancer Drugs Product
Table 114. Argos Therapeutics Recent Developments/Updates
Table 115. ArQule Corporation Information
Table 116. ArQule Description and Business Overview
Table 117. ArQule Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. ArQule Kidney Cancer Drugs Product
Table 119. ArQule Recent Developments/Updates
Table 120. AVEO Pharmaceuticals Corporation Information
Table 121. AVEO Pharmaceuticals Description and Business Overview
Table 122. AVEO Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. AVEO Pharmaceuticals Kidney Cancer Drugs Product
Table 124. AVEO Pharmaceuticals Recent Developments/Updates
Table 125. Bionomics Corporation Information
Table 126. Bionomics Description and Business Overview
Table 127. Bionomics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. Bionomics Kidney Cancer Drugs Product
Table 129. Bionomics Recent Developments/Updates
Table 130. Bristol-Myers Squibb Corporation Information
Table 131. Bristol-Myers Squibb Description and Business Overview
Table 132. Bristol-Myers Squibb Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. Bristol-Myers Squibb Kidney Cancer Drugs Product
Table 134. Bristol-Myers Squibb Recent Developments/Updates
Table 135. Cerulean Pharma Corporation Information
Table 136. Cerulean Pharma Description and Business Overview
Table 137. Cerulean Pharma Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. Cerulean Pharma Kidney Cancer Drugs Product
Table 139. Cerulean Pharma Recent Developments/Updates
Table 140. Exelixis Corporation Information
Table 141. Exelixis Description and Business Overview
Table 142. Exelixis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 143. Exelixis Kidney Cancer Drugs Product
Table 144. Exelixis Recent Developments/Updates
Table 145. Genentech Corporation Information
Table 146. Genentech Description and Business Overview
Table 147. Genentech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 148. Genentech Kidney Cancer Drugs Product
Table 149. Genentech Recent Developments/Updates
Table 150. immatics biotechnologies Corporation Information
Table 151. immatics biotechnologies Description and Business Overview
Table 152. immatics biotechnologies Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 153. immatics biotechnologies Kidney Cancer Drugs Product
Table 154. immatics biotechnologies Recent Developments/Updates
Table 155. Immunicum Corporation Information
Table 156. Immunicum Description and Business Overview
Table 157. Immunicum Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 158. Immunicum Kidney Cancer Drugs Product
Table 159. Immunicum Recent Developments/Updates
Table 160. Ono Pharmaceutical Corporation Information
Table 161. Ono Pharmaceutical Description and Business Overview
Table 162. Ono Pharmaceutical Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 163. Ono Pharmaceutical Kidney Cancer Drugs Product
Table 164. Ono Pharmaceutical Recent Developments/Updates
Table 165. Onyx Therapeutics Corporation Information
Table 166. Onyx Therapeutics Description and Business Overview
Table 167. Onyx Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 168. Onyx Therapeutics Kidney Cancer Drugs Product
Table 169. Onyx Therapeutics Recent Developments/Updates
Table 170. Oxford BioMedica Corporation Information
Table 171. Oxford BioMedica Description and Business Overview
Table 172. Oxford BioMedica Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 173. Oxford BioMedica Kidney Cancer Drugs Product
Table 174. Oxford BioMedica Recent Developments/Updates
Table 175. Prometheus Laboratories Corporation Information
Table 176. Prometheus Laboratories Description and Business Overview
Table 177. Prometheus Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 178. Prometheus Laboratories Kidney Cancer Drugs Product
Table 179. Prometheus Laboratories Recent Developments/Updates
Table 180. Seattle Genetics Corporation Information
Table 181. Seattle Genetics Description and Business Overview
Table 182. Seattle Genetics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 183. Seattle Genetics Kidney Cancer Drugs Product
Table 184. Seattle Genetics Recent Developments/Updates
Table 185. Taiwan Liposome Corporation Information
Table 186. Taiwan Liposome Description and Business Overview
Table 187. Taiwan Liposome Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 188. Taiwan Liposome Kidney Cancer Drugs Product
Table 189. Taiwan Liposome Recent Developments/Updates
Table 190. Tracon Pharmaceuticals Corporation Information
Table 191. Tracon Pharmaceuticals Description and Business Overview
Table 192. Tracon Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 193. Tracon Pharmaceuticals Kidney Cancer Drugs Product
Table 194. Tracon Pharmaceuticals Recent Developments/Updates
Table 195. Wilex Corporation Information
Table 196. Wilex Description and Business Overview
Table 197. Wilex Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 198. Wilex Kidney Cancer Drugs Product
Table 199. Wilex Recent Developments/Updates
Table 200. Key Raw Materials Lists
Table 201. Raw Materials Key Suppliers Lists
Table 202. Kidney Cancer Drugs Distributors List
Table 203. Kidney Cancer Drugs Customers List
Table 204. Kidney Cancer Drugs Market Trends
Table 205. Kidney Cancer Drugs Market Drivers
Table 206. Kidney Cancer Drugs Market Challenges
Table 207. Kidney Cancer Drugs Market Restraints
Table 208. Research Programs/Design for This Report
Table 209. Key Data Information from Secondary Sources
Table 210. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Kidney Cancer Drugs
Figure 2. Global Kidney Cancer Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Kidney Cancer Drugs Market Share by Type in 2023 & 2030
Figure 4. Angiogenesis Inhibitors Product Picture
Figure 5. mTOR Inhibitors Product Picture
Figure 6. Monoclonal Antibodies Product Picture
Figure 7. Cytokine Immunotherapy (IL-2) Product Picture
Figure 8. Global Kidney Cancer Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Kidney Cancer Drugs Market Share by Application in 2023 & 2030
Figure 10. Renal Cell Carcinoma (RCC)
Figure 11. Transitional Cell Carcinoma (TCC)
Figure 12. Global Kidney Cancer Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Kidney Cancer Drugs Market Size (2019-2030) & (US$ Million)
Figure 14. Global Kidney Cancer Drugs Sales (2019-2030) & (K Units)
Figure 15. Global Kidney Cancer Drugs Average Price (USD/Unit) & (2019-2030)
Figure 16. Kidney Cancer Drugs Report Years Considered
Figure 17. Kidney Cancer Drugs Sales Share by Manufacturers in 2023
Figure 18. Global Kidney Cancer Drugs Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Kidney Cancer Drugs Players: Market Share by Revenue in 2023
Figure 20. Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Kidney Cancer Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Kidney Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 23. North America Kidney Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 24. U.S. Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Kidney Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 27. Europe Kidney Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 28. Germany Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Kidney Cancer Drugs Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Kidney Cancer Drugs Revenue Market Share by Region (2019-2030)
Figure 35. China Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Taiwan Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Philippines Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Kidney Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 46. Latin America Kidney Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Kidney Cancer Drugs Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Kidney Cancer Drugs Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. U.A.E Kidney Cancer Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Kidney Cancer Drugs by Type (2019-2030)
Figure 56. Global Revenue Market Share of Kidney Cancer Drugs by Type (2019-2030)
Figure 57. Global Kidney Cancer Drugs Price (USD/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Kidney Cancer Drugs by Application (2019-2030)
Figure 59. Global Revenue Market Share of Kidney Cancer Drugs by Application (2019-2030)
Figure 60. Global Kidney Cancer Drugs Price (USD/Unit) by Application (2019-2030)
Figure 61. Kidney Cancer Drugs Value Chain
Figure 62. Kidney Cancer Drugs Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock